Compare Nurix Therapeutics, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 1,928 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.14
-65.76%
5.18
Revenue and Profits:
Net Sales:
44 Million
(Quarterly Results - May 2025)
Net Profit:
-43 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.78%
0%
21.78%
6 Months
-24.98%
0%
-24.98%
1 Year
8.03%
0%
8.03%
2 Years
63.21%
0%
63.21%
3 Years
63.54%
0%
63.54%
4 Years
-43.36%
0%
-43.36%
5 Years
0%
0%
0.0%
Nurix Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
35.30%
EBIT Growth (5y)
-228.42%
EBIT to Interest (avg)
-164.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
0.23
Tax Ratio
0.41%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.03
EV to EBIT
-1.87
EV to EBITDA
-2.02
EV to Capital Employed
-6.94
EV to Sales
7.64
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-43.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Aug 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 55 Schemes (45.77%)
Foreign Institutions
Held by 112 Foreign Institutions (15.86%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - May'25 - QoQ
May'25
Nov'24
Change(%)
Net Sales
44.10
13.30
231.58%
Operating Profit (PBDIT) excl Other Income
-43.20
-60.40
28.48%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-43.50
-58.50
25.64%
Operating Profit Margin (Excl OI)
-1,096.80%
-4,867.30%
377.05%
USD in Million.
Net Sales
Not Applicable: The company has declared_date for only one period
Consolidated Net Profit
Not Applicable: The company has declared_date for only one period
Annual Results Snapshot (Consolidated) - Nov'24
Nov'24
Nov'23
Change(%)
Net Sales
54.50
77.00
-29.22%
Operating Profit (PBDIT) excl Other Income
-196.60
-141.40
-39.04%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-193.60
-143.90
-34.54%
Operating Profit Margin (Excl OI)
-3,905.20%
-2,014.10%
-189.11%
USD in Million.
Net Sales
YoY Growth in year ended Nov 2024 is -29.22% vs 99.48% in Nov 2023
Consolidated Net Profit
YoY Growth in year ended Nov 2024 is -34.54% vs 20.23% in Nov 2023
About Nurix Therapeutics, Inc. 
Nurix Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Nurix Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. It uses its DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases. Its drug candidate includes NX-2127, NX-5948, NX-1607 and DeTIL-0255. Its lead drug candidate, NX-2127, is an orally available Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. Its lead drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Its E3 ligase inhibitor portfolio is comprised of a series of small molecule inhibitors of CBL-B, which functions as an intracellular checkpoint regulating activation of T cells, B-cells and NK cells.
Company Coordinates 
Company Details
1700 Owens St Ste 205 , SAN FRANCISCO CA : 94158-0006
Registrar Details






